Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q13838

UPID:
DX39B_HUMAN

ALTERNATIVE NAMES:
56 kDa U2AF65-associated protein; ATP-dependent RNA helicase p47; DEAD box protein UAP56; HLA-B-associated transcript 1 protein

ALTERNATIVE UPACC:
Q13838; B0S8C0; O43496; Q0EFA1; Q2L6F9; Q53GL9; Q5RJ64; Q5RJ66; Q5ST94; Q5STB4; Q5STB5; Q5STB7; Q5STB8; Q5STU4; Q5STU5; Q5STU6; Q5STU8; Q71V76

BACKGROUND:
DDX39B, integral to the TREX complex, is crucial for mRNA transcription, processing, and nuclear export. It associates with spliced mRNA, aiding in its export to the cytoplasm via the TAP/NFX1 pathway. DDX39B's ATPase activity, stimulated by RNA and ALYREF/THOC4, is vital for loading components onto mRNA. Additionally, it plays a role in the nuclear export of intronless mRNA and is essential for the export of Kaposi's sarcoma-associated herpesvirus (KSHV) intronless mRNAs.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Spliceosome RNA helicase DDX39B could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.